Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: Results from a randomized controlled trial

British Journal of Dermatology

Volumn 171, Issue 5, 2014, Pages 1215-1219

  Zhu, B ^a   Edson Heredia, E ^a   Guo, J ^b   Maeda Chubachi, T ^a   Shen, W ^a   Kimball, A B ^c  

^a ELI LILLY AND COMPANY   (United States)

^b SYNEOS HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IXEKIZUMAB; PLACEBO; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN RELATION; LEISURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; PRURITUS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL; VISUAL ANALOG SCALE; WORK; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PSORIASIS; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PRURITUS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84911391640     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13065     Document Type: Article

References (17)

1. Schäfer I, Hacker J, Rustenbach SJ, et al,. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol 2010; 20: 62-7.
2. Reich K, Griffiths CE,. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res 2008; 300: 537-44.
3. Revicki DA, Willian MK, Menter A, et al,. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008; 216: 260-70.
4. Mattei PL, Corey KC, Kimball AB,. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014; 28: 333-7.
5. European Dermatology Forum. (2009) EDF guidelines for dermatology in Europe. Available at: http://www.abw-verlag.com/db-picture.php?120;BOOKS-BookList;Leseprobe (last accessed 1 October 2014).
6. Yosipovitch G, Goon A, Wee J, et al,. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143: 969-73.
7. Zachariae R, Zachariae CO, Lei U, Pedersen AF,. Affective and sensory dimensions of pruritus severity: associations with psychological symptoms and quality of life in psoriasis patients. Acta Derm Venereol 2008; 88: 121-7.
8. Zachariae R, Lei U, Haedersdal M, Zachariae C,. Itch severity and quality of life in patients with pruritus: preliminary validity of a Danish adaptation of the itch severity scale. Acta Derm Venereol 2012; 92: 508-14.
9. Schneider G, Driesch G, Heuft G, et al,. Psychosomatic cofactors and psychiatric comorbidity in patients with chronic itch. Clin Exp Dermatol 2006; 31: 762-7.
10. Leonardi C, Matheson R, Zachariae C, et al,. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-9.
11. Louden BA, Pearce DJ, Lang W, Feldman SR,. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J 2004; 10: 7.
12. Langley RG, Ellis CN,. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51: 563-9.
13. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
14. Basra MK, Fenech R, Gatt RM, et al,. The Dermatology Quality of Life Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997-1035.
15. Cardiff University. Dermatology Life Quality Index. Available at: http://www.dermatology.org.uk/quality/dlqi/quality-dlqi-info.html (last accessed on 1 October 2014).
16. Sobel ME,. Asymptotic confidence intervals for indirect effects in structural equation models. Sociol Methodol 1982; 13: 290-312.
17. Preacher KJ, Kelley K,. Effect size measures for mediation models: quantitative strategies for communicating indirect effects. Psychol Methods 2011; 16: 93-115.